DiaMedica is a biopharmaceutical company focused on the novel treatment of diabetes and neurological disorders. The Company has discovered a critical brain to liver nerve signal mechanism involved in enhancing insulin sensitivity of skeletal muscle after meal consumption. With this proprietary knowledge and understanding, the Company has been able to mimic this brain-liver nerve signal pathway, which is impaired in people with Type 2 diabetes, leading to increased or restored insulin sensitivity. The Company has successfully completed three phase II proof-of-concept trials that act on this pathway. DiaMedica’s DM-99/199 program has also shown the ability to protect and proliferate beta cells (diabetes) and neural cells (neurological disorders).

The June 2010 acquisition of Sanomune Inc. has enabled DiaMedica to expand its DM-199 program into autoimmune and neurological disorders. Both DiaMedica and Sanomune were recognized as one of Canada’s Top 10™ Life Sciences Companies in 2008/2009.

The company is listed on the TSX Venture Exchange under the trading symbol “DMA”.